Harpoon Therapeutics Stock Forecast, Price & News

-0.27 (-2.53 %)
(As of 07/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume759,758 shs
Average Volume343,796 shs
Market Capitalization$338.25 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Harpoon Therapeutics logo

About Harpoon Therapeutics

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.87 out of 5 stars

Medical Sector

431st out of 2,214 stocks

Biological Products, Except Diagnostic Industry

64th out of 213 stocks

Analyst Opinion: 4.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

Is Harpoon Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Harpoon Therapeutics stock.
View analyst ratings for Harpoon Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Harpoon Therapeutics?

Wall Street analysts have given Harpoon Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Harpoon Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,960,000 shares, an increase of 69.0% from the June 15th total of 1,160,000 shares. Based on an average daily volume of 318,300 shares, the short-interest ratio is currently 6.2 days. Approximately 9.6% of the shares of the company are sold short.
View Harpoon Therapeutics' Short Interest

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Harpoon Therapeutics

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) issued its earnings results on Thursday, May, 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. The business earned $9.01 million during the quarter, compared to analyst estimates of $6.80 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 68.36% and a negative net margin of 428.95%.
View Harpoon Therapeutics' earnings history

How has Harpoon Therapeutics' stock price been impacted by Coronavirus?

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HARP stock has decreased by 20.4% and is now trading at $10.40.
View which stocks have been most impacted by COVID-19

What price target have analysts set for HARP?

8 analysts have issued 1 year target prices for Harpoon Therapeutics' stock. Their forecasts range from $25.00 to $40.00. On average, they anticipate Harpoon Therapeutics' share price to reach $32.88 in the next year. This suggests a possible upside of 216.1% from the stock's current price.
View analysts' price targets for Harpoon Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the following people:
  • Dr. Gerald McMahon, Pres, CEO & Director (Age 66, Pay $832.05k)
  • Ms. Georgia L. Erbez, Chief Financial Officer (Age 54, Pay $554.55k)
  • Dr. Natalie R. Sacks, Chief Medical Offer (Age 56, Pay $633.35k)
  • Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 53)
  • Ms. Rachael Lester, VP of Corp. Devel.
  • Dr. Susan Dana Jones Ph.D., Sr. VP of Product Devel.
  • Dr. Che-Leung Law Ph.D., Sr. VP of Translational Medicine
  • Mr. Christopher Whitmore, VP of Fin. & Sec.

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

4 employees have rated Harpoon Therapeutics CEO Gerald McMahon on Gerald McMahon has an approval rating of 100% among Harpoon Therapeutics' employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Harpoon Therapeutics' key competitors?

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $10.40.

How much money does Harpoon Therapeutics make?

Harpoon Therapeutics has a market capitalization of $338.25 million and generates $17.44 million in revenue each year. The company earns $-49,910,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis.

How many employees does Harpoon Therapeutics have?

Harpoon Therapeutics employs 84 workers across the globe.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is

Where are Harpoon Therapeutics' headquarters?

Harpoon Therapeutics is headquartered at 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.